Get the Stockscreener App
15.98
1.66%
-0.27
After Hours:
15.98
Bicara Therapeutics Inc stock is traded at $15.98, with a volume of 594.10K.
It is down -1.66% in the last 24 hours and down -6.22% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$16.25
Open:
$16.03
24h Volume:
594.10K
Relative Volume:
1.14
Market Cap:
$871.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.00%
1M Performance:
-6.22%
6M Performance:
+10.21%
1Y Performance:
-33.44%
1-Day Range:
$15.49
$16.65
1-Week Range:
$15.42
$17.71
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
15.98 | 887.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
What risks investors should watch in Bicara Therapeutics Inc. stockPortfolio Return Report & Weekly High Momentum Picks - newser.com
Real time alert setup for Bicara Therapeutics Inc. performanceEarnings Growth Report & Risk Controlled Daily Plans - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockJuly 2025 EndofMonth & Low Drawdown Momentum Ideas - newser.com
Why Bicara Therapeutics Inc. stock appeals to analystsWeekly Trade Review & Safe Entry Trade Signal Reports - newser.com
Is Bicara Therapeutics Inc. stock a buy before product launchesFed Meeting & Safe Capital Growth Stock Tips - newser.com
How Bicara Therapeutics Inc. stock benefits from global expansion2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
How to manage a losing position in Bicara Therapeutics Inc.Jobs Report & Technical Pattern Based Buy Signals - newser.com
How currency fluctuations impact Bicara Therapeutics Inc. stock2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
Analyzing Bicara Therapeutics Inc. with risk reward ratio charts2025 Macro Impact & AI Driven Stock Movement Reports - newser.com
Will Bicara Therapeutics Inc. stock see insider buyingSell Signal & Verified Stock Trade Ideas - newser.com
How Bicara Therapeutics Inc. stock compares to market leadersJuly 2025 Rallies & Stepwise Trade Signal Implementation - newser.com
Why Bicara Therapeutics Inc. stock is considered a top pickTrade Ideas & Safe Capital Preservation Plans - newser.com
How institutional buying supports Bicara Therapeutics Inc. stockPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Will Bicara Therapeutics Inc. stock benefit from automationJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
What institutional flow reveals about Bicara Therapeutics Inc.Earnings Beat & Risk Controlled Stock Alerts - newser.com
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):